New Study Reveals First Genetic Links in ME and Chronic Fatigue Syndrome Paving the Way for New Diagnostics and Drugs
PrecisionLife Reports 14 Genes Associated with ME/CFS at the M.E. Genetics Research Summit in Edinburgh
OXFORD, UK, September 14, 2022 – PrecisionLife, a pioneering techbio company generating the deepest insights into disease biology to create novel precision medicines for chronic diseases, today unveiled the results of its study that provides the first detailed genetic insights into the pathophysiological mechanisms underpinning Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This is the first time that replicable genetic findings have been reported in over 30 years of study into the disease, offering new approaches for better diagnosis and treatment of patients.
The results of the ME/CFS study are being presented today at the M.E. Genetics Research Summit organized by ME charity, Action for M.E. and the MRC Human Genetics Unit, University of Edinburgh. The data has also been submitted for peer reviewed publication and is available on the pre-publication site medRxiv, here: https://www.medrxiv.org/content/10.1101/2022.09.09.22279773v1.
The use of a new hypothesis-free combinatorial analytics approach using the PrecisionLife™ platform enabled the study to identify 14 novel genetic associations with ME/CFS from the UK Biobank cohort. Specifically, the combinatorial analysis revealed 199 SNPs, mapping to these 14 genes, that were significantly associated with 91% of the cases in the ME/CFS population. Many of these genes are involved in highly plausible cellular mechanisms associated with ME/CFS disease including vulnerabilities to stress and infection, mitochondrial dysfunction, sleep disturbance and autoimmune development.
The study also identified similarities with genes that PrecisionLife has found to be associated with multiple sclerosis (MS) and long COVID.
ME/CFS is a debilitating chronic disease affecting around 17 million people worldwide, which presents with diverse symptoms including post-exertional malaise, chronic pain, and cognitive impairment. There are currently no approved disease modifying therapies for ME/CFS, and patients are managed via prescription of drugs and other therapies for symptomatic relief, including pain relief, anti-depressants, and cognitive behavioural therapy.
Sonya Chowdhury, Chief Executive, Action for M.E., said: “For too long, people with ME/CFS have struggled to get their condition diagnosed, understood, and acknowledged. These are exciting findings from PrecisionLife that may be used to develop diagnostic biomarkers and discover novel drug targets and precision repositioning opportunities in the future. If successful, these could be used to create the first therapeutic options for this debilitating disease.”
Dr Steve Gardner, CEO, PrecisionLife, added: “These groundbreaking results provide new hope of developing effective precision medicines for people living with ME/CFS around the world. It is further validation for our unique approach to the analysis of complex disease biology. PrecisionLife now has this unprecedented level of insight across over 40 diseases that we have so far studied, which creates wonderful opportunities for us and our partners to bring novel solutions for patients with unmet medical needs.”
MS and ME/CFS patients share a number of similar symptoms and there is increasing evidence that many long COVID patients also share similar symptoms. It is also believed that some patients may be developing ME/CFS symptoms as a direct result of having a COVID-19 infection.
PrecisionLife is in the process of analyzing long COVID-19 and MS populations to identify shared genes and biological mechanisms underpinning ME/CFS, MS and long COVID-19 development. Establishing the similarities and differences between them in more detail is likely to have profound implications for patients and the development of novel diagnostic and therapeutic tools.
Preliminary findings from the PrecisionLife long COVID analysis have indicated that three of the genes identified its ME/CFS study are also significant in the long COVID patient group. These will be subject of further validation in a new publication later this year.
Next, PrecisionLife aims to replicate and extend the results of this UK Biobank study with combinatorial analysis of the DecodeME study, the largest genetic ME/CFS study, with over 20,000 participants. This is likely to allow further insights into the different subgroups and targets involved with the disease.
Caption: Disease architecture diagram demonstrating 15 groups of SNPs that make up the structure of ME/CFS patient sub-populations identified by the PrecisionLife study. Each circle represents a disease-associated SNP genotype, edges represent their co-association in patients in disease signature(s), and colours represent distinct patient sub-populations. On the right: the same disease architecture view coloured to show the critical SNPs associated with each community.
PrecisionLife is a pioneering techbio company changing the way we predict, prevent, and treat chronic diseases. Its unique combinatorial analytics approach generates more insights from patient data than any other method, revealing the drivers of complex disease biology and stratifying patients at an unprecedented level of resolution.
This deeper understanding of disease biology powers PrecisionLife's innovation engine of patient-focused drug discovery, derisked clinical development, and accurate diagnostics, delivering a new age of better, more personalized therapy options – improving health, for everyone.
PrecisionLife is developing an in-house pipeline of novel early-stage drug discovery targets with patient stratification biomarkers and precision repositioning assets for co-development with biopharma partners in over 40 chronic diseases.
For more information visit www.precisionlife.com or follow PrecisionLife on LinkedIn and Twitter.
Steve Gardner, CEO
T: +44 (0)1865 575170
WG Partners LLP
David Wilson, Nigel Barnes, Parthiv Patel
T: +44 (0) 20 3705 9321
Press Contact (for PrecisionLife)
T: +44 (0)7968 726585